Log in

Relevant bibliographies by topics / Branded vs. Generic / Journal articles

To see the other types of publications on this topic, follow the link: Branded vs. Generic.

Journal articles on the topic 'Branded vs. Generic'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Branded vs. Generic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dennen, Syvart, Marty Masek, Sai Sriteja Boppudi Naga, Paul Cockrum, and Ravi Kumar Paluri. "Costs of generic vs. branded nab-paclitaxel (nP) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with gemcitabine + nab-paclitaxel (GnP) in a real-world commercial database." Journal of Clinical Oncology 43, no. 4_suppl (2025): 694. https://doi.org/10.1200/jco.2025.43.4_suppl.694.

Full text

Abstract:

694 Background: In 2013, the FDA approved GnP for 1L treatment of mPDAC. The total cost of care (TCoC) to payers during treatment is driven by the cost of nP, which first faced competition from generics in April 2022. We examined cost per generic vs. branded nP claim and cost per patient (pt) before and after generic entry. Methods: This retrospective observational study utilized Optum Market Clarity claims + EHR data. Inclusion criteria were: adult pts diagnosed with mPDAC between January 1, 2015 and May 31, 2023; initiated 1L GnP (index date) -14 to +90 days from diagnosis; 6 months pre-inde

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Generic vs branded carbamazepine interchangeable?" Inpharma Weekly &NA;, no. 1194 (1999): 20. http://dx.doi.org/10.2165/00128413-199911940-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

MURALI, R., B. PRAVEENA, and K. BALAMURUGAN. "Invitro evaluation of generic vs branded product of metformin tablet." World Journal of Advanced Research and Reviews 21, no. 3 (2024): 1490–95. https://doi.org/10.5281/zenodo.14135710.

Full text

Abstract:

The main aim and objective of present research work is to evaluate and compare the standards concerning quality of generic and branded anti hyperglycemic drug (Metformin Hcl). Metformin tablets are evaluated as per standard protocol and results shows that branded and generic meets the pharmacopoeial specifications. All tablets passed the test of weight variation, hardness, thickeness, friability, disintegration, dissolution and assay as per Indian pharmacopoeia. Both the generic and branded tablets of metformin shows similar results. So, health care professionals are suggested to prescribe gen

APA, Harvard, Vancouver, ISO, and other styles

4

MURALI R, PRAVEENA B, and BALAMURUGAN K. "Invitro evaluation of generic vs branded product of metformin tablet." World Journal of Advanced Research and Reviews 21, no. 3 (2024): 1490–95. http://dx.doi.org/10.30574/wjarr.2024.21.3.0768.

Full text

Abstract:

The main aim and objective of present research work is to evaluate and compare the standards concerning quality of generic and branded anti hyperglycemic drug (Metformin Hcl). Metformin tablets are evaluated as per standard protocol and results shows that branded and generic meets the pharmacopoeial specifications. All tablets passed the test of weight variation, hardness, thickeness, friability, disintegration, dissolution and assay as per Indian pharmacopoeia. Both the generic and branded tablets of metformin shows similar results. So, health care professionals are suggested to prescribe gen

APA, Harvard, Vancouver, ISO, and other styles

5

Ananthoju, Viswasanthi, Sankar Kurli, Satya Gopal P., and Ravi Prasad Nidanapu. "Assessing the Therapeutic Outcomes and Safety of Generic vs Branded Teneligliptin in Type-2 Diabetic Patients: A Lipid Profile Perspective." International Journal of Pharmaceutical and Clinical Research 16, no. 10 (2024): 425–31. https://doi.org/10.5281/zenodo.14036828.

Full text

Abstract:

<strong>Background:</strong> Teneligliptin is a DPP-4 inhibitor widely used in the management of Type-2 Diabetes Mellitus (T2DM) to improve glycemic control. While both branded and generic versions are available, there is limited data comparing their therapeutic efficacy and safety, particularly concerning lipid profiles and renal function. This study aimed to compare the therapeutic outcomes and safety profiles of branded versus generic Teneligliptin in managing glycemic control and lipid profiles in patients with Type-2 Diabetes Mellitus (T2DM). <strong>Methods:</strong> A tot

APA, Harvard, Vancouver, ISO, and other styles

6

SANDHIYA J and BALAMURUGAN K. "A comparative analysis on generic product vs branded product of prednisolone tablet." GSC Biological and Pharmaceutical Sciences 26, no. 3 (2024): 050–54. http://dx.doi.org/10.30574/gscbps.2024.26.3.0089.

Full text

Abstract:

The main aim and objective of present research work is to evaluate and compare the standard concerning quality of generic and branded anti-inflammatory drug. The drug are evaluated and research showed that branded and generic meet the Pharmacopoeial specification. All tablet passed for the test of weight variation, hardness, thickness, friability, disintegration, dissolution as per pharmacopeia. Hence, we can say that branded and nonbranded drugs of anti-inflammatory are equal. So, healthcare professionals are suggested to prescribe generic drugs so that everyone can reach the cost of drugs an

APA, Harvard, Vancouver, ISO, and other styles

7

SANDHIYA, J., and K. BALAMURUGAN. "A comparative analysis on generic product vs branded product of prednisolone tablet." GSC Biological and Pharmaceutical Sciences 26, no. 3 (2024): 050–54. https://doi.org/10.5281/zenodo.11044572.

Full text

Abstract:

The main aim and objective of present research work is to evaluate and compare the standard concerning quality of generic and branded anti-inflammatory drug. The drug are evaluated and research showed that branded and generic meet the Pharmacopoeial specification. All tablet passed for the test of weight variation, hardness, thickness, friability, disintegration, dissolution as per pharmacopeia. Hence, we can say that branded and nonbranded drugs of anti-inflammatory are equal. So, healthcare professionals are suggested to prescribe generic drugs so that everyone can reach the cost of drugs an

APA, Harvard, Vancouver, ISO, and other styles

8

T, Tamilveeran, Karthikeyan B, and Balamurugan K. "A Comparison and Evaluation of Loop Diuretic Frusemide Generic vs Brand Tablets." Journal of Pharmaceutical Research International 36, no. 4 (2024): 24–32. http://dx.doi.org/10.9734/jpri/2024/v36i47509.

Full text

Abstract:

Branded medications are the original products developed by pharmaceutical companies and generic drugs are copies of branded drugs whose patent has expired. The research work focused on comparisons and evaluations of generic VS brand of frusemide tablets. The study includes some of the specifications that should tested in the finished products in tablets such as appearance, thickness, diameter, weight variation, hardness, friability, disintegration time, dissolution, hardness and thickness as per pharmacopoeial & non pharmacopoeial tests were performed. The generic and brand frusemide table

APA, Harvard, Vancouver, ISO, and other styles

9

Arcaniolo, Davide, Carlos Miacola, Marco Bitelli, et al. "Comparative Effectiveness of Dalerpen vs. Branded and Other Generic Tadalafil: The “Shift Study”." Uro 5, no. 3 (2025): 14. https://doi.org/10.3390/uro5030014.

Full text

Abstract:

Background: Phosphodiesterase type 5 inhibitors (PDE5i), particularly tadalafil and sildenafil, are the first-line therapies for erectile dysfunction (ED). After the patent expiration of branded tadalafil in 2017, generic formulations became available. Despite equivalent efficacy, skepticism persists regarding the effectiveness and safety of generics. The SHIFT study aimed to evaluate the non-inferiority of a generic tadalafil (Dalerpen) compared with branded and other generic tadalafil in terms of clinical efficacy and patient satisfaction. Methods: A prospective, multicenter study was conduc

APA, Harvard, Vancouver, ISO, and other styles

10

Walenga, Jeanine M., Walter Jeske, Debra Hoppensteadt, et al. "Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin." Blood 120, no. 21 (2012): 2264. http://dx.doi.org/10.1182/blood.v120.21.2264.2264.

Full text

Abstract:

Abstract Abstract 2264 Background: Low molecular weight heparins (LMWHs) are complex biologic drugs whose heterogeneity in saccharide chain length and in the composition (sulfate, acetyl), content, and location of functional groups can impact their multiple biologic activities. Enoxaparin (Lovenox®) is validated for multiple indications and is the most widely used LMWH in the US. Several generic versions of enoxaparin are currently available in the US. We undertook this study to compare the activity profile of branded and a generic enoxaparin. Methods: Five batches each of branded (B; Sanofi-a

APA, Harvard, Vancouver, ISO, and other styles

11

Gandhi, Santosh V., and Mohitosh R. Mahajan. "Method development, validation and comparative study of generic Vs. branded generic formulations of amoxicillin trihydrate in capsule dosage form." Journal of Drug Delivery and Therapeutics 9, no. 3-s (2019): 186–92. http://dx.doi.org/10.22270/jddt.v9i3-s.2821.

Full text

Abstract:

The present work relates to development and validation of simple, precise and sensitive UV spectrometric and high-performance thin layer chromatographic (HPTLC) method for the analysis of Amoxicillin Trihydrate in Capsule dosage form. Method were developed and applied for comparative study of generic vs branded generic formulations of Amoxicillin Trihydrate. Amoxicillin Trihydrate in methanol shows maximum absorbance at 229 nm and the data of linear regression analysis indicated a good linear relationship over the concentration range of 5-30 µg/ml with a correlation coefficient (R2) 0.998 by U

APA, Harvard, Vancouver, ISO, and other styles

12

Ya’u, Jamilu, Abdulnasir Salihu, Shuaibu Aliyu, Musa Usman, Nuhu Danjuma, and Ibrahim Abdu-Aguye. "Comparative Antiseizure Activities of Some Branded and Generic Antiepileptic Drugs in a Nigerian City." NIgerian Journal of Neuroscience 13, no. 4 (2022): 111–18. http://dx.doi.org/10.47081/njn2022.13.4/001.

Full text

Abstract:

Branded antiepileptic drugs (AEDs) are expensive, and in developing countries, cheaper generic equivalents may be used interchangeably. Therefore, this study aimed to compare the antiseizure activities of some available branded and generic AEDs in mice. The physicochemical properties of four generic and branded AEDs (carbamazepine, CAB; sodium valproate, SVP; phenytoin, PHY, and phenobarbitone, PHB) were determined according to pharmacopoeial methods. The organoleptic proper-ties, tablet hardness and thickness of the samples were also assessed. The anticonvulsant effect of AEDs was determined

APA, Harvard, Vancouver, ISO, and other styles

13

Dou, Xuelin, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, and Qian Jiang. "Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study." Blood 134, Supplement_1 (2019): 2940. http://dx.doi.org/10.1182/blood-2019-130081.

Full text

Abstract:

Objectives To compare the efficacy and safety of Chinese generic imatinib with branded imatinib in adults with newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). Methods Data of adults with newly diagnosed CML-CP receiving Chinese generic imatinib (Xinwei®, Hansoh, China; Genike®, Chiatai Tianqing, China) or branded imatinib (Glivec®, Novartis, Basel, Switzerland) between October 2013 and August 2018, during which both of the agents were commercially available in China, were retrospectively reviewed. Propensity score matching (PSM) case-control study was performed. Assessm

APA, Harvard, Vancouver, ISO, and other styles

14

Suthar, Jalpa, and Shrina Patel. "A Comparison of Pharmacy Students' and Community Pharmacists' Knowledge, Attitude, and Practise of Generic vs. Branded Medicines." Journal of Medical Research and Reviews 1, no. 2 (2023): 36. http://dx.doi.org/10.5455/jmrr.20230908033552.

Full text

Abstract:

Background: In most of the developing countries, generic medicines are not as frequently prescribed due to a lack of knowledge and awareness. Generic substitution is considered as a major cost minimizing strategy without compromising healthcare quality. This study aimed to compare and evaluate Knowledge, Attitude, and Practice among Community Registered Pharmacists and Students of Pharmacy. Materials and Methods: A Cross-sectional Questionnaire-based study was conducted among pharmacy students and pharmacy professionals, consisting of questions related to knowledge, attitude, and practice rega

APA, Harvard, Vancouver, ISO, and other styles

15

Cetean, Sînziana, Călin Căinap, Olga Soriţău, et al. "Platinum derivatives: generic brands vs. original, in vitro tests." Revista Romana de Medicina de Laborator 23, no. 4 (2015): 439–48. http://dx.doi.org/10.1515/rrlm-2015-0043.

Full text

Abstract:

Abstract The entry of the generic drugs on the market was an impressive development of the pharmaceutical industry and due to their lower prices also a decrease in the cost price for the treatment of patients. The difference in price (sometimes even 50%) between generics and original and different response to therapy sometimes raised serious questions related to their therapeutic equivalence. The scientific community is increasingly interested in this aspect, with studies (in vitro and on patients) demonstrated statistically significant differences in terms of differences generic / original dr

APA, Harvard, Vancouver, ISO, and other styles

16

Alshammari, Elham. "Efficacy of Generic vs. branded Isotretinoin for Acne treatment: a case report." Journal Of Advanced Pharmacy Education And Research 11, no. 1 (2021): 125–27. http://dx.doi.org/10.51847/uvtefaq1oi.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Gomes, Marise, Eduardo Ramacciotti, Alexandre Cruz Henriques, et al. "Generic Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery." Clinical and Applied Thrombosis/Hemostasis 17, no. 6 (2011): 633–39. http://dx.doi.org/10.1177/1076029611418967.

Full text

Abstract:

Introduction: Several generic low-molecular-weight heparins (LMWHs) have recently become available worldwide, including the United States. Companies have filed for regulatory approval of generic versions in many countries, based only on compound biochemical characteristics or its immunogenicity. Methods: Prospective study to evaluate the comparative effect of 2 enoxaparins (Sanofi-Aventis branded enoxaparin [SAe] vs eurofarma-enoxaparin [Ee], a generic version) as prophylaxis for venous thromboembolism (VTE) following major abdominal surgery. A total of 200 patients were randomized in a 1:1 ra

APA, Harvard, Vancouver, ISO, and other styles

18

Shinde, Namdeo G., Sakshi Salunke, Rutuja Salunke, Rutika Jadhav, Ahilya Kale, and Pravin Doke. "Comparative in-vitro evaluation of marketed formulations (Branded Vs Generic) Crocin 650 Vs Solo 650 tablets." International Journal of Pharmaceutical Research and Development 7, no. 1 (2025): 465–74. https://doi.org/10.33545/26646862.2025.v7.i1f.140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

E. Waterlander, Wilma, Marita van Kouwen, and Ingrid H.M. Steenhuis. "Are diets healthier when they contain branded foods?" British Food Journal 116, no. 10 (2014): 1522–32. http://dx.doi.org/10.1108/bfj-08-2013-0226.

Full text

Abstract:

Purpose – Market trend data show a growing popularity of discount food stores and of cheaper food products as opposed to more expensive leading brands (LB). Unexpectedly little is known about how these economic food choices affect diet quality and/or health. The purpose of this paper is to examine differences in nutrient content and cost of daily food intake data modeled to contain food exclusively from either LB, generic brands (GB) or discount brands (DB). Design/methodology/approach – This study analyzed nutrition information of 430 food products that were selected based on dietary intake d

APA, Harvard, Vancouver, ISO, and other styles

20

Fareed, Jawed, Debra Hoppensteadt, Omer Iqbal, Jeanine M. Walenga, and Bruce E. Lewis. "Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays." Blood 116, no. 21 (2010): 5129. http://dx.doi.org/10.1182/blood.v116.21.5129.5129.

Full text

Abstract:

Abstract Abstract 5129 Several generic versions of argatroban) (Mitsubishi; Tokyo, Japan) have been introduced in Japan (Argaron, Gartban, Slovastan). In addition, other generic versions of argatroban are being considered by the European and North American regulatory bodies. While the generic versions of argatroban exhibit similar antithrombin potency (Ki values), because of the differential compositional variations their anticoagulant effects in whole blood systems may differ due to their cellular and plasmatic protein interactions. Branded and generic versions of argatroban may exhibit diffe

APA, Harvard, Vancouver, ISO, and other styles

21

Kozaric, Amina Kurtovic, Erna Islamagic, Jerald P. Radich, Emina Suljovic Hadzimesic, Azra Hasic, and Sabira Kurtovic. "The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina." Blood 128, no. 22 (2016): 5451. http://dx.doi.org/10.1182/blood.v128.22.5451.5451.

Full text

Abstract:

Abstract Introduction Imatinib mesylate (Glivec, Novartis) is the first tyrosine kinase inhibitor (TKI) targeting the BCR-ABL1 fusion protein responsible for the pathogenesis of chronic myeloid leukemia (CML). Low cost generic alternatives to imatinib are an integral part of cost effective healthcare strategies for developing countries. However, the use of generics has been associated with different clinical outcomes. In this study, we compared outcomes of two groups of patients who received Glivec as first-line therapy (Group 1) to patients who received generic imatinib as first-line therapy

APA, Harvard, Vancouver, ISO, and other styles

22

Frois, Christian, Thomas O’Connell, Jacqueline Pesa, and John Fastenau. "The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication." Journal of Health Economics and Outcomes Research 1, no. 1 (2013): 54–61. http://dx.doi.org/10.36469/9853.

Full text

Abstract:

Background: Few studies have attempted to assess the effectiveness of formulary management in reducing the antipsychotic costs and utilization across U.S. state Medicaid programs, despite concerns about the potential impact of such formulary management on Medicaid patient health outcomes. Objectives: Compare antipsychotic utilization and total costs across Medicaid states with preferred drug list (PDL) programs vs. states without PDLs in place. Methods: The following data from 48 Medicaid fee-for-service (FFS) programs were collected for calendar year 2010: antipsychotic prescription use (IMS

APA, Harvard, Vancouver, ISO, and other styles

23

Pirk, O., HJ Schultes, and FU Fricke. "PRK3 BRANDED VS GENERIC CYCLOSPORINE IN DE-NOVO KIDNEY TRANSPLANTATION—WHERE ARE THE COST SAVINGS?" Value in Health 5, no. 6 (2002): 581–82. http://dx.doi.org/10.1016/s1098-3015(10)61528-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cheng, Ming, Chris K. Anderson, Zhen Zhu, and S. Chan Choi. "Service online search ads: from a consumer journey view." Journal of Services Marketing 32, no. 2 (2018): 126–41. http://dx.doi.org/10.1108/jsm-06-2016-0224.

Full text

Abstract:

Purpose This study aims to address the following research questions: Do the two types of service firms (individual or aggregator) have similar competitiveness on online search ads? How should the two types of service firms select optimal branded keywords to improve search performance? In addition, how do consumers’ search queries influence the service search performance of the two types of service firms? Design/methodology/approach In this study, the authors conduct an empirical analysis by building a two-stage choice modeling on the process of search engine ranking and consumer click-through

APA, Harvard, Vancouver, ISO, and other styles

25

Zhao, J., H. Huang, and Z. Zhang. "AB0509 CLINICAL EQUIVALENCE OF GENERIC AND BRANDED TOFACITINIB IN REAL-WORLD: A PROSPECTIVE LONGITUDINAL COHORT STUDY IN RHEUMATOID ARTHRITIS PATIENTS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1449.1–1449. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2267.

Full text

Abstract:

BackgroundThe efficacy and safety of Xeljanz® have also been confirmed in RA patients. Varieties of generic tofacitinib have been developed in different countries. However, there is no study comparing the efficacy and safety between generic and brand-name tofacitinib yet.ObjectivesIn the current study, we compared the efficacy, safety, and cost-effectiveness between a Chinese generic tofacitinib Kelejia® and the brand-name tofacitinib Xeljanz® in RA patients from a prospective real-world cohort.MethodsRA patients receiving tofacitinib, either generic (Kelejia®, generic group) or branded (Xelja

APA, Harvard, Vancouver, ISO, and other styles

26

Muir, Michele, Jasmine Johnson, Sitong Shu, Hui-Han Chen, Sachiko Ozawa, and Benyam Muluneh. "Evaluating Real-World Effectiveness and Safety of Generic and Brand-Name Imatinib in Chronic Myeloid Leukemia." Blood 138, Supplement 1 (2021): 3614. http://dx.doi.org/10.1182/blood-2021-149309.

Full text

Abstract:

Abstract Introduction: Generic formulations of imatinib were approved and commercially available in the United States starting in 2016, introducing vast cost savings to the standard treatment of chronic myeloid leukemia (CML). While bioequivalence studies of generic formulations are required for Food and Drug Administration approval, the safety of generic drug supply chains have come into question. There is limited real-world data comparing the effectiveness and safety profiles of generic formulations to the original. This study aimed to evaluate the effectiveness and safety of generic imatini

APA, Harvard, Vancouver, ISO, and other styles

27

Qian, Jingjing, Ahmed Ullah Mishuk, and Richard A. Hansen. "Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs." Expert Opinion on Drug Safety 17, no. 8 (2018): 753–56. http://dx.doi.org/10.1080/14740338.2018.1503648.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Khan, Mariya P., P. N. Khandelwal, Chitrita Kishore, and Anushka Singh. "Study of prescription pattern of topical antimicrobials used for eye infections in ophthalmology." International Journal of Basic & Clinical Pharmacology 14, no. 3 (2025): 367–74. https://doi.org/10.18203/2319-2003.ijbcp20251062.

Full text

Abstract:

Background: The use of topical antibacterial medicines for the treatment of patients with infections in the eye has various advantages with some disadvantages. After literature search, I was unable to find a larger number of articles on eye infections, so I selected this study in this particular area. Methods: It was observational cross-sectional study; 270 patients were enrolled who visited the Ophthalmology OPD with a diagnosis of eye infections. Results: The mean age±SD were 39.53 (±16.30). The 40.37% patients were suffering from conjunctivitis. The most commonly prescribed dosage forms wer

APA, Harvard, Vancouver, ISO, and other styles

29

Worley, Daniel G., Iryna Melnyk, Dawn Johannesen, Jennifer Ellis, and Pamela Landsman-Blumberg. "Real-world comparison of adherence to branded 20 mg dexamethasone tablets and generic 4 mg dexamethasone tablets among patients with multiple myeloma." Journal of Clinical Oncology 42, no. 16_suppl (2024): e19518-e19518. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e19518.

Full text

Abstract:

e19518 Background: Branded 20 mg dexamethasone tablets (BDex) is the first and only FDA-approved dexamethasone specifically indicated for the treatment of adult patients with multiple myeloma (MM) in combination with other anti-myeloma products. Generic oral dexamethasone is only available at lower dosages (e.g., 4 mg) despite the standard dexamethasone dosage for MM being 20 or 40 mg. The availability of 20 mg tablets would, therefore, reduce pill burden and assumably improve adherence in MM patients. The objective of this analysis was to quantify and compare adherence of BDex and generic 4 m

APA, Harvard, Vancouver, ISO, and other styles

30

Tripathi, Shailesh, and Sudip Bhattacharya. "Patient Perception about Generic vs. Branded Medicines Prescribed in a Tertiary Care Hospital in Northern India -A Descriptive Study." Indian Journal of Pharmacy Practice 11, no. 2 (2018): 91–95. http://dx.doi.org/10.5530/ijopp.11.2.19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Dharmapriya, H. A. T., H. M. L. S. Nikathenna, T. P. K. Jayasiri, D. H. A. Mendis, and W. M. K. M. Ratnayake. "Preliminary Study on Evaluation of Knowledge, Attitudes and Practices (KAP) of Pharmacy Workers on Generic Vs. Branded Medicine in Colombo District, Sri Lanka." CINEC Academic Journal 6, no. 2 (2024): 87–93. http://dx.doi.org/10.4038/caj.v6i2.130.

Full text

Abstract:

Pharmacists, apprentice pharmacists and non-pharmacists belong to the same umbrella of pharmacy workers as they all work in a pharmacy. They perform a wide range of tasks within the pharmacy. In addition to ensuring that the medications patients are prescribed are appropriate, speciality pharmacists also help patients with concerns and provide advice on how to take their medications and potential side effects. Therefore, pharmacy employees must have the right knowledge, attitudes, and behaviours for a pharmacy to run well and to provide the right medication along with the right guidance. This

APA, Harvard, Vancouver, ISO, and other styles

32

Giere, Isabel Amanda, María Jose Mela Osorio, Federico Andrés Klosowski, et al. ""M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study." Blood 128, no. 22 (2016): 5445. http://dx.doi.org/10.1182/blood.v128.22.5445.5445.

Full text

Abstract:

Abstract Introduction: Early reduction of BCR-ABL transcript level has been associated with improved outcomes in CML treatment. Inability to achieve early molecular response(MR) at 3 months (M3>10%) is considered a predictor factor for unfavourable outcome. However, the kinetics of BCR-ABL transcript level reduction measured at early time points have shown to be an independent predictor of response.The aim of this analysis was to determine whether the "M3-M6" status is critical to categorize CML patients (pts) focusing in high-risk group. Method: Molecular monitoring was performed in all pt

APA, Harvard, Vancouver, ISO, and other styles

33

Maria, Vinky, William Nathanial Tjandrawidjaya, Ayu Rahmawati, Prih Sarnianto, Yusi Anggriani, and Elizabeth Pisani. "Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia." BMJ Global Health 10, no. 5 (2025): e015416. https://doi.org/10.1136/bmjgh-2024-015416.

Full text

Abstract:

BackgroundSince Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Industry groups warn unsustainably low prices threaten quality, while the government says medicines remain overpriced. We investigate the relationship between the price and quality of essential medicines and the affordability of medicines paid for out of pocket.MethodsWe bought over 1000 samples of five common prescription medicines—allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone—online and from randomly sel

APA, Harvard, Vancouver, ISO, and other styles

34

Kozaric, Amina Kurtovic, Erna Islamagic, Semir Beslija, Sabira Kurtovic, Lejla Mehinovic, and Azra Hasic. "Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience." Journal of Clinical Oncology 35, no. 15_suppl (2017): e18549-e18549. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18549.

Full text

Abstract:

e18549 Background: In this study we examined the long-term real life clinical outcomes of patients receiving front- line nilotinib and patients who switched from branded or generic imatinib to nilotinib (second-line therapy) in Bosnia and Herzegovina. Methods: Patients in CML-CP (n = 70) who started their TKI treatment in period from June 2005 to August 2016 were included in this multicentre retrospective cohort study. Patients were categorized as: Group 1 (n = 31) contained patients receiving front-line nilotinib (300 mg twice daily) and Group 2 (n = 39) consisted of patients who started with

APA, Harvard, Vancouver, ISO, and other styles

35

Kuhn, Robert J., Sabine Eyting, Friederike Henniges, and Andreas Potthoff. "In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution." Journal of Pediatric Pharmacology and Therapeutics 12, no. 2 (2007): 115–28. http://dx.doi.org/10.5863/1551-6776-12.2.115.

Full text

Abstract:

OBJECTIVE Pancreatic enzyme products were available before the 1938 passage of the Federal Food, Drug, and Cosmetic Act and have to date been marketed without required safety and efficacy testing. Despite a lack of demonstrated bioequivalence, they are often substituted for each other without physician or patient consent or monitoring. We investigated the in vitro variability of key performance parameters among a representative group of currently available pancreatic enzyme formulations. MATERIALS AND METHODS Three “branded” preparations (Creon 20 Minimicrospheres, Pancrease MT 20, Ultrase MT

APA, Harvard, Vancouver, ISO, and other styles

36

Jeske, Walter P., Jeanine M. Walenga, Debra Hoppensteadt, Elizabeth McGeehan, Michelle Kujawski, and Mamdouh Bakhos. "Pharmacodynamic Differentiation of Generic Low Molecular Weight Heparins." Blood 110, no. 11 (2007): 1871. http://dx.doi.org/10.1182/blood.v110.11.1871.1871.

Full text

Abstract:

Abstract Generic LMWHs are available in several countries and several products are currently under review by the FDA. Because there are no regulatory guidelines for defining equivalence of complex biologic drugs, studies were performed to determine whether anti-FXa potency and mean molecular weight are sufficient properties to characterize a generic LMWH as equivalent to the innovator product. Previous in vitro studies have shown differences between generic and name-brand versions of LMWHs in terms of oligosaccharide composition, anticoagulant/anti-protease activity and protamine neutralizatio

APA, Harvard, Vancouver, ISO, and other styles

37

Wongcharoen, Wanwarang, Amarase Pamarapa, Siriluck Gunaparn, and Arintaya Phrommintikul. "Anti-Factor Xa Activity of Apixaban in Extremely Low Body Weight." Journal of Clinical Medicine 14, no. 15 (2025): 5238. https://doi.org/10.3390/jcm14155238.

Full text

Abstract:

Background: Direct oral anticoagulants (DOACs) are generally preferred over warfarin for preventing arterial and venous thromboembolism. However, the efficacy and safety of DOACs in patients with extremely low body weight (BW) are uncertain. This study investigates anti-factor Xa (anti-FXa) activity of apixaban and compares it between patients with normal BW (>50 kg) and underweight (≤50 kg). Methods: We enrolled 150 patients on branded generic apixaban (ApixanTM) for atrial fibrillation (AF), venous thromboembolism, and intracardiac thrombus. Anti-FXa activity of apixaban was measured at p

APA, Harvard, Vancouver, ISO, and other styles

38

Mitchell, Aaron Philip, Caroline Carlin, Roger Feldman, Ge Song, and Jeah Jung. "Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare." Journal of Clinical Oncology 43, no. 16_suppl (2025): 11075. https://doi.org/10.1200/jco.2025.43.16_suppl.11075.

Full text

Abstract:

11075 Background: Medicare Advantage (MA) has steadily grown during the past decade, covering over half of Medicare beneficiaries in 2024. Because MA plans receive capitated payments for Medicare beneficiaries, they have the financial incentives to reduce service utilization and costs. MA plans may discourage enrollees from using low-value services, such as medically unnecessary care and expensive treatments for which low-cost alternatives are available. No prior study examining the use of low-value services between MA and TM has evaluated the use of low-value cancer treatments specifically. W

APA, Harvard, Vancouver, ISO, and other styles

39

Hirsch, Jared, Paul Cockrum, Samantha Tomicki, Gabriela Dieguez, Prachi Bhatt, and George P. Kim. "Components of total cost of care in real-world patients with mPDAC who received first-line FOLFIRINOX or Gem/Abrax." Journal of Clinical Oncology 41, no. 16_suppl (2023): e16282-e16282. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16282.

Full text

Abstract:

e16282 Background: FOLFIRINOX (FFX) and Gemcitabine/Abraxane (Gem/Abrax) are two recommended options for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). There is limited research assessing differences in costs between real-world patients with mPDAC who received first-line (1L) FFX or Gem/Abrax. Methods: We used ICD-10 diagnosis codes to identify patients aged 65+ with mPDAC without end-stage renal disease in the 2018-2021 Medicare Parts A, B, and D 100% Research Identifiable Files (RIF) data. Total cost of care (TCOC) represents mean Medicare paid amounts and patient cost

APA, Harvard, Vancouver, ISO, and other styles

40

Mattingly, T. Joseph, Gerard F. Anderson, and Joseph F. Levy. "Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications." JAMA Health Forum 4, no. 6 (2023): e231317. http://dx.doi.org/10.1001/jamahealthforum.2023.1317.

Full text

Abstract:

ImportanceMeasuring drug price inflation is challenging because new drugs continually enter the market, some drugs transition from branded to generic, and current inflation indexes do not account for these market basket changes. Instead, they measure the price increases after new drugs have been launched. Therefore, the public pays the higher costs of newer and usually more expensive drugs, but the inflation indexes do not reflect the increases over existing drugs previously used to treat the same conditions.ObjectiveTo assess how price index methods can affect estimates of drug price inflatio

APA, Harvard, Vancouver, ISO, and other styles

41

Gomes, Marise, Eduardo Ramacciotti, Debra Hoppensteadt, et al. "An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers." Blood 116, no. 21 (2010): 1086. http://dx.doi.org/10.1182/blood.v116.21.1086.1086.

Full text

Abstract:

Abstract Abstract 1086 Biosimilar enoxaparin preparations are in use outside the U.S. Due to compositional variations, their interaction with platelet factor 4 (PF4) differs leading to differential immunogenic responses between branded and biosimilar agents. To compare their immunogenic response, branded enoxaparin (Clexane®, Sanofi-Aventis) and a biosimilar version (Cutenox®, Gland-Pharma) were administered to healthy volunteers (n=110/drug) at a dose of 40 mg SQ for10 days. Blood samples drawn on days 1 and 10 were analyzed for anti-heparin/PF4 antibody (A-HPF4-Ab) titers and subtypes by ELI

APA, Harvard, Vancouver, ISO, and other styles

42

Han, Seung Hwan, Gyu Chul Oh, Hyuck Moon Kwon, et al. "Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study." Drug Design, Development and Therapy Volume 12 (December 2018): 4217–29. http://dx.doi.org/10.2147/dddt.s172046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Franceschetti, Alessandra. "NHL and rituximab biosimilar: How have prescribing behaviours changed in EU5 in 15 months?" Journal of Clinical Oncology 37, no. 15_suppl (2019): e19054-e19054. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e19054.

Full text

Abstract:

e19054 Background: 15 months after EMA approval of the first rituximab biosimilar to treat NHL – and 12 months on from our presentation on its initial impact at the Biosimilars Special Clinical Symposium of ASCO 2018 – this study tracks the real world impact of official endorsement on prescribing behaviour and biosimilar adoption for NHL. Methods: The Ipsos Global Oncology Monitor – an online multi-country, multi-centre medical chart review of NHL patients, where 138 geographically representative physicians provided de-identified data on 3,239 patients treated with anti-cancer drugs in France

APA, Harvard, Vancouver, ISO, and other styles

44

Botteman, Marc, Matthew Magestro, Alaa Fadhil Alwan, Paul W. Manley, Oleg Zernovak та Richard C. Woodman. "Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate". Blood 120, № 21 (2012): 4439. http://dx.doi.org/10.1182/blood.v120.21.4439.4439.

Full text

Abstract:

Abstract Abstract 4439 Background: Several reports have recently been published documenting the experience of patients with Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase (CML-CP) who were switched from Glivec (IM), the β-crystalline form of imatinib mesylate, to non-identical alternate copies of imatinib mesylate (IMac) including those composed of the α-crystalline form. As a result of pre-clinical tests performed during the early development of IM, the β-crystalline form of imatinib mesylate was selected for further development due to its superior stability. I

APA, Harvard, Vancouver, ISO, and other styles

45

Shafrin, Jason, Nadine Zawadzki, Shurui Zhang, Paul Pinkston, David Wei, and Jennifer E. Vaughn. "Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers." Blood 144, Supplement 1 (2024): 3677. https://doi.org/10.1182/blood-2024-201000.

Full text

Abstract:

INTRODUCTION: Later-generation tyrosine kinase inhibitors (TKIs) have achieved deeper and more rapid molecular responses in chronic myeloid leukemia (CML) compared to first-generation TKI imatinib. However, the cost of these newer treatments has raised concerns about the financial impact imparted to patients and payers. This study measured the financial impact, as the burden to patients based on either (i) out-of-pocket (OOP) costs or (ii) changes in insurance premiums, of newer TKIs relative to imatinib in publicly and privately insured US populations. METHODS: Patient financial impact was me

APA, Harvard, Vancouver, ISO, and other styles

46

Larson, Richard A., Rena Conti, William V. Padula, et al. "What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?" Blood 124, no. 21 (2014): 738. http://dx.doi.org/10.1182/blood.v124.21.738.738.

Full text

Abstract:

Abstract We analyzed and compared the cost-effectiveness of 2 strategies for treating CML patients -- using imatinib first in all (altering therapy as needed in a stepwise approach) or by physician’s choice, starting either imatinib or one of the approved second-generation tyrosine kinase inhibitors (TKIs) dasatinib or nilotinib. Currently, each TKI is patent-protected and commands about one-third of front-line CML treatment. Life-long treatment is recommended. Imatinib is losing patent exclusivity and facing generic competition presently in the US (in early 2016) and in EU member countries; i

APA, Harvard, Vancouver, ISO, and other styles

47

Dotsenko, Elena G. "Melodramatic Tradition vs Colorblind Casting for Branden Jacobs-Jenkins’ Plays." Literature of the Americas, no. 16 (2024): 190–208. http://dx.doi.org/10.22455/2541-7894-2024-16-190-208.

Full text

Abstract:

The article concerns with the plays An Octoroon and Gloria by contemporary American playwright Branden Jacobs-Jenkins. The dramaturgy of one of the most notable authors, writing for the US theatre at the present time, is thematically varied; besides, it includes both Jacobs-Jenkins’ original works (e.g., Gloria, 2015) and his adaptations of plays by other authors and/or other epochs. Among the adaptations there is the most famous of Jacobs-Jenkins' plays so far — An Octoroon (2014), which is the author's treatment of 19th century melodrama The Octoroon (1859) by Anglo-Irish dramatist Dion Bouc

APA, Harvard, Vancouver, ISO, and other styles

48

Polanowski, Piotr, Krzysztof Hałagan, and Andrzej Sikorski. "Star Polymers vs. Dendrimers: Studies of the Synthesis Based on Computer Simulations." Polymers 14, no. 13 (2022): 2522. http://dx.doi.org/10.3390/polym14132522.

Full text

Abstract:

A generic model was developed for studies of the polymerization process of regular branched macromolecules. Monte Carlo simulations were performed employing the Dynamic Lattice Liquid algorithm to study this process. A core-first methodology was used in a living polymerization of stars with up to 32 arms, and dendrimers consisted of 4-functional segments. The kinetics of the synthesis process for stars with different numbers of branches and dendrimers was compared. The size and structure of star-branched polymers and dendrimers during the synthesis were studied. The influence of the functional

APA, Harvard, Vancouver, ISO, and other styles

49

Zhang, W., D. Guh, H. Sun, et al. "AB1591 POLICY DRIVERS FOR MARKET PENETRATION OF ANTI-TNF BIOSIMILARS: MULTI-COUNTRY COMPARISONS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 2029.2–2030. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1464.

Full text

Abstract:

BackgroundHealth systems across countries have used different policy measures (e.g. price discounts, tendering, mandating switches) to encourage the introduction of biosimilars but their differential impact on market penetration is unknown.ObjectivesTo evaluate the impact of policy measures on market penetration of anti-TNF biosimilars.MethodsQuarterly IQVIA MIDAS sales data from 2012-2021 for infliximab, etanercept and adalimumab in 5 countries (Canada, France, Germany, Italy and the United Kingdom (UK)) that used different policy tools were used. Biosimilar market penetration was measured by

APA, Harvard, Vancouver, ISO, and other styles

50

SUDASINGHE, HIRANYA, R. H. THARINDU RANASINGHE, SAMPATH de ALWIS GOONATILAKE, and MADHAVA MEEGASKUMBURA. "A review of the genus Labeo (Teleostei: Cyprinidae) in Sri Lanka." Zootaxa 4486, no. 3 (2018): 201. http://dx.doi.org/10.11646/zootaxa.4486.3.1.

Full text

Abstract:

The taxonomy of the three native taxa assigned to the genus Labeo (L. dussumieri, L. fisheri and L. porcellus lankae) in Sri Lanka is reviewed. The population hitherto identified as L. dussumieri in Sri Lanka is shown to be a distinct species, here named L. heladiva. Labeo heladiva, new species, has a wide distribution in the low and mid-elevations of the island and is distinguished from its Indian congeners by the combination of having two pairs of barbels; 12–13 branched dorsal-fin rays; lateral line with 44–51 scales; ½8–½9+1+6–7 scales in transverse series; and 19–22 circumpeduncular scale

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!